扩散加权磁共振成像为评估前列腺癌患者放疗疗效提供了一种有用的生物标志物。
Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer.
作者信息
Wu Xingchen, Reinikainen Petri, Kapanen Mika, Vierikko Tuula, Ryymin Pertti, Kellokumpu-Lehtinen Pirkko-Liisa
机构信息
Department of Oncology, Medical Imaging Centre, Tampere University Hospital, Tampere, Finland
Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
出版信息
Anticancer Res. 2017 Sep;37(9):5027-5032. doi: 10.21873/anticanres.11917.
BACKGROUND
Diffusion-weighted imaging (DWI) with measurement of apparent diffusion coefficient (ADC) allows for assessment of tumor aggressiveness. The objective of this study was to evaluate the changes of ADC value in prostate cancer after volumetric-modulated arc radiotherapy (VMAT) and to identify magnetic resonance imaging (MRI) biomarkers for monitoring tissue changes after radiotherapy.
PATIENTS AND METHODS
Thirty-seven patients with biopsy-proven prostate cancer treated with VMAT underwent serial MRI examinations including DWI before radiotherapy, and at 3 and 12 months after radiotherapy. ADC values of the tumor and healthy prostate tissue were measured and compared at these three time points.
RESULTS
The tumor ADC value increased significantly 3 months after radiotherapy (p<0.0001). There was a further increase of tumor ADC from 3 to 12 months after radiotherapy (p<0.01). The ADC of healthy prostate tissue did not show any significant changes.
CONCLUSION
The ADC value is a useful biomarker for evaluating the efficacy of radiotherapy in prostate cancer.
背景
通过测量表观扩散系数（ADC）的扩散加权成像（DWI）可用于评估肿瘤侵袭性。本研究的目的是评估容积调强弧形放疗（VMAT）后前列腺癌ADC值的变化，并确定用于监测放疗后组织变化的磁共振成像（MRI）生物标志物。
患者与方法
37例经活检证实的前列腺癌患者接受了VMAT治疗，并在放疗前、放疗后3个月和12个月进行了包括DWI在内的系列MRI检查。在这三个时间点测量并比较肿瘤和健康前列腺组织的ADC值。
结果
放疗后3个月肿瘤ADC值显著升高（p<0.0001）。放疗后3至12个月肿瘤ADC值进一步升高（p<0.01）。健康前列腺组织的ADC值未显示任何显著变化。
结论
ADC值是评估前列腺癌放疗疗效的有用生物标志物。
Zotero 插件